Ratings PROCEPT BioRobotics Corporation

Equities

PRCT

US74276L1052

Real-time Estimate Cboe BZX Other stock markets 10:13:36 2024-05-03 am EDT			5-day change	1st Jan Change
63 ^USD	+2.05%		+19.70%	+48.03%

May. 02	Truist Raises PROCEPT BioRobotics' PT to $72 From $63 After 'Solid' Q1 Beat, Keeps Buy Rating	MT
May. 01	Procept BioRobotics Shares Rise After Q1 Loss Narrows, Revenue Increases; 2024 Revenue Guidance Revised	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
PROCEPT BIOROBOTICS CORPORATION	+48.03%	3.17B	-
ABBOTT LABORATORIES	-3.43%	184B	C+
MEDTRONIC PLC	-0.76%	107B	C
BECTON, DICKINSON AND COMPANY	-1.64%	69.44B	A
DEXCOM, INC.	+3.07%	50.37B	B-
CENCORA, INC.	+8.83%	44.82B	B-
HOYA CORPORATION	+3.40%	41.53B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+4.51%	26.84B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	+4.94%	26.73B	B
TERUMO CORPORATION	+15.23%	25.71B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes